Apollo Therapeutics Ltd

This early-stage trial is testing a new vaccine called APL-10456 that targets rhinovirus, the main cause of the common cold. About 144 healthy adults, both younger (18-54) and older (55+), will receive either the vaccine or a placebo. The main goal is to check if the vaccine is s…